Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
ACE Report #6162
Ace Report Cover Metabolic Disorders

Osteoporosis: Weekly 28.2ug teriparatide reduces vertebral fracture risk

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Once-Weekly Injection of Low-Dose Teriparatide (28.2 ug) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis

Calcif Tissue Int. 2014 Feb;94(2):170-5. doi: 10.1007/s00223-013-9777-8. Epub 2013 Aug 21

Contributing Authors: T Fujita M Fukunaga A Itabashi K Tsutani T Nakamura

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


316 primary osteoporosis patients were randomized to receive a 28.2ug injection of teriparatide or placebo injection (1.4ug teriparatide) once-weekly for 3 years, to determine the effects of teriparatide on vertebral fracture prevention and lumbar spine BMD. Results indicated that teriparatide reduced the risk of vertebral fractures and increased lumbar bone mineral density compared to placebo, bu...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.